Moderna's COVID-19 vaccine stable at refrigerator temperature for 30 days

American drug maker Moderna has said that its COVID-19 vaccine remains stable in refrigerators for 30 days, a revelation that eases concerns around large scale rollout. Moderna Inc. on vember 16 anunced that its vaccine candidate mRNA-1273 has proven to be 94.5% effective. Later, company anunced that drug could also be stored at 36 degrees to 46 degrees Fahrenheit for up to 30 days. In dition, vaccine also remained stable for 12 hours at room temperature. 

Speaking to CNBC, company’s CEO  Stephane Bancel, said that drug could also be stored for longer-term and shipped. In that case, vaccine just needs to be kept at freezer temperature of -4 degrees Fahrenheit, a temperature that distributers were alrey familiar with. Bancel also stressed that Moderna’s vaccine, unlike it’s competitors, won’t require dilution before it's ministered to patients ding that it was a ““big differentiator of product.”

Re: Moderna Says Its COVID-19 Shot Is 94.5% Effective

Re: POTUS Donald Trump Jumps To Take Credit As Moderna Anunce 94.5% COVID Vaccine Efficacy

Moderna anunces 94.5% Efficacy of COVID vaccine

Anuncing results of its phase three trials, Moderna on vember 16 reported that its COVID-19 vaccine candidate has proven to be 94.5% effective. biotechlogy company has informed that it intends to submit COVID-19 vaccine candidate for an Emergency Use Authorization (EUA) with United States' Food & Drug ministration (FDA). analysis released by Moderna which has reported 94.5% efficacy of COVID-19 vaccine was based on results of more than 30,000 participants in US. 

analysis report of Moderna vaccine revealed that 'preliminary analysis suggests a broly consistent safety and efficacy profile across all evaluated subgroups. Moderna's Phase 3 trials are randomized and including providing vaccine shots at 100 µg dose level in 30,000 participants in U.S., s 18 and older. 

On vember 10, Pfizer Inc anunced that its mRNA-based COVID-19 vaccine candidate which was found 90 per cent effective in first interim analysis from Phase III study, will be distributed in December across US, Pfizer confirmed in a press release. Developed with German partner BioNTech SE, Pfizer’s COVID-19 vaccine was declared effective against SARS-CoV-2 by independent Data Monitoring Committee (DMC) in an analysis conducted on vember 8, 2020. 

Re: POTUS Donald Trump Jumps To Take Credit As Moderna Anunce 94.5% COVID Vaccine Efficacy

Re: UK Starts Real-time Review Of Moderna's COVID-19 Vaccine To Reduce 'time To Authorisation'